JP2023542092A5 - - Google Patents
Info
- Publication number
- JP2023542092A5 JP2023542092A5 JP2023515682A JP2023515682A JP2023542092A5 JP 2023542092 A5 JP2023542092 A5 JP 2023542092A5 JP 2023515682 A JP2023515682 A JP 2023515682A JP 2023515682 A JP2023515682 A JP 2023515682A JP 2023542092 A5 JP2023542092 A5 JP 2023542092A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- administered
- bispecific antibody
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063076818P | 2020-09-10 | 2020-09-10 | |
| US63/076,818 | 2020-09-10 | ||
| US202163164255P | 2021-03-22 | 2021-03-22 | |
| US63/164,255 | 2021-03-22 | ||
| PCT/EP2021/075022 WO2022053658A1 (en) | 2020-09-10 | 2021-09-10 | Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023542092A JP2023542092A (ja) | 2023-10-05 |
| JP2023542092A5 true JP2023542092A5 (https=) | 2024-09-18 |
Family
ID=77914295
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023515682A Pending JP2023542092A (ja) | 2020-09-10 | 2021-09-10 | びまん性大細胞型ｂ細胞リンパ腫を治療するための併用療法におけるｃｄ３及びｃｄ２０に対する二重特異性抗体 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20230312759A1 (https=) |
| EP (1) | EP4210745A1 (https=) |
| JP (1) | JP2023542092A (https=) |
| KR (1) | KR20230066392A (https=) |
| AU (1) | AU2021342343A1 (https=) |
| BR (1) | BR112023004319A2 (https=) |
| CA (1) | CA3192256A1 (https=) |
| IL (1) | IL301100A (https=) |
| MX (1) | MX2023002541A (https=) |
| WO (1) | WO2022053658A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2022013797A (es) | 2020-05-08 | 2022-11-30 | Genmab As | Anticuerpos biespecificos contra cd3 y cd20. |
| CN116782933A (zh) | 2020-09-10 | 2023-09-19 | 健玛保 | 用于治疗弥漫性大b细胞淋巴瘤的联合疗法中的针对cd3和cd20的双特异性抗体 |
| KR20230066040A (ko) | 2020-09-10 | 2023-05-12 | 젠맵 에이/에스 | 만성 림프구성 백혈병을 치료하기 위한 cd3 및 cd20에 대한 이중특이적 항체 |
| CA3189883A1 (en) | 2020-09-10 | 2022-03-17 | Brian Elliott | Bispecific antibody against cd3 and cd20 in combination therapy for treating follicular lymphoma |
| CA3190376A1 (en) | 2020-09-10 | 2022-03-17 | Brian Elliott | Bispecific antibody against cd3 and cd20 in combination therapy for treating follicular lymphoma |
| US20240034812A1 (en) | 2020-09-10 | 2024-02-01 | Genmab A/S | Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma |
| WO2024236031A1 (en) | 2023-05-15 | 2024-11-21 | Genmab A/S | Highly purified epcoritamab compositions |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| GB9203459D0 (en) | 1992-02-19 | 1992-04-08 | Scotgen Ltd | Antibodies with germ-line variable regions |
| ATE299938T1 (de) | 1997-05-02 | 2005-08-15 | Genentech Inc | Ein verfahren zur herstellung multispezifischer antikörper die heteromultimere und gemeinsame komponenten besitzen |
| BRPI0315295C1 (pt) | 2002-10-17 | 2021-05-25 | Genmab As | anticorpo monoclonal humano isolado, célula hospedeira procariótica, composição farmacêutica, molécula biespecífica, usos de um anticorpo, métodos in vitro de detectar a presença de antígeno de cd20 ou uma célula que expressa cd20 em uma amostra, kit, e, vetor de expressão |
| AU2006232287B2 (en) | 2005-03-31 | 2011-10-06 | Chugai Seiyaku Kabushiki Kaisha | Methods for producing polypeptides by regulating polypeptide association |
| CA2631184A1 (en) | 2005-11-28 | 2007-05-31 | Genmab A/S | Recombinant monovalent antibodies and methods for production thereof |
| JP6157046B2 (ja) | 2008-01-07 | 2017-07-05 | アムジェン インコーポレイテッド | 静電的ステアリング（ｅｌｅｃｔｒｏｓｔａｔｉｃｓｔｅｅｒｉｎｇ）効果を用いた抗体Ｆｃヘテロ二量体分子を作製するための方法 |
| WO2010129304A2 (en) | 2009-04-27 | 2010-11-11 | Oncomed Pharmaceuticals, Inc. | Method for making heteromultimeric molecules |
| AR080794A1 (es) | 2010-03-26 | 2012-05-09 | Hoffmann La Roche | Anticuerpos bivalentes biespecificos anti- vegf/ anti-ang-2 |
| HRP20241208T1 (hr) | 2010-04-20 | 2024-11-22 | Genmab A/S | Heterodimerni proteini koji sadrže fc fragment protutijela i postupci za njihovu proizvodnju |
| SG11201401422VA (en) | 2011-10-27 | 2014-09-26 | Genmab As | Production of heterodimeric proteins |
| ME03675B (me) | 2013-07-05 | 2020-10-20 | Genmab As | Humanizovana ili himerna anтi-cd3 antiтela |
| US10544220B2 (en) * | 2015-01-08 | 2020-01-28 | Genmab A/S | Bispecific antibodies against CD3 and CD20 |
| JP7784795B2 (ja) * | 2016-11-15 | 2025-12-12 | ジェネンテック， インコーポレイテッド | 抗ｃｄ２０／抗ｃｄ３二重特異性抗体による処置のための投与 |
| CN111787948A (zh) | 2018-02-09 | 2020-10-16 | 健玛保 | 包含针对cd3和cd20的双特异性抗体的药物组合物及其用途 |
-
2021
- 2021-09-10 EP EP21777656.6A patent/EP4210745A1/en active Pending
- 2021-09-10 KR KR1020237011606A patent/KR20230066392A/ko active Pending
- 2021-09-10 WO PCT/EP2021/075022 patent/WO2022053658A1/en not_active Ceased
- 2021-09-10 MX MX2023002541A patent/MX2023002541A/es unknown
- 2021-09-10 CA CA3192256A patent/CA3192256A1/en active Pending
- 2021-09-10 US US18/025,208 patent/US20230312759A1/en active Pending
- 2021-09-10 IL IL301100A patent/IL301100A/en unknown
- 2021-09-10 JP JP2023515682A patent/JP2023542092A/ja active Pending
- 2021-09-10 BR BR112023004319A patent/BR112023004319A2/pt unknown
- 2021-09-10 AU AU2021342343A patent/AU2021342343A1/en active Pending
- 2021-12-22 US US17/559,965 patent/US20220112309A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023542092A5 (https=) | ||
| JP2023542290A5 (https=) | ||
| JP2023541860A5 (https=) | ||
| JP2023542289A5 (https=) | ||
| JP2023541858A5 (https=) | ||
| JP2023542291A5 (https=) | ||
| JP7766392B2 (ja) | 治療用抗ｃｄ４０リガンド抗体 | |
| CN106795219A (zh) | 抗il‑17抗体及其生产和使用的方法 | |
| JP2023524149A5 (https=) | ||
| JP2020504723A5 (https=) | ||
| JP2021514973A5 (https=) | ||
| US20240392003A1 (en) | Multispecific antibodies having specificity for ror1 and cd3 | |
| JP2021524478A5 (https=) | ||
| JP2025032102A5 (https=) | ||
| JP2024532489A5 (https=) | ||
| JP2019517540A5 (https=) | ||
| JP2021512107A5 (https=) | ||
| JP2024534602A5 (https=) | ||
| JP2025508317A5 (https=) | ||
| JP2020505350A5 (https=) | ||
| JP2025503176A5 (https=) | ||
| JP2025503177A5 (https=) | ||
| JP2024509332A5 (https=) | ||
| IL319999A (en) | Bispecific antibodies against CD3 and CD20 - for the treatment of Richter syndrome | |
| IL314341A (en) | Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma |